The US drug manufacturer recalled the Eliquis (apixaban) Lot - number #HN0063 - on Friday, explaining that it was a precautionary measure prompted by a customer compliant.
B-MS said it had not received reports of adverse events adding that the “distinct visible differences” between the two tablet strengths “decrease the likelihood of an incorrect dose.”
A spokeswoman told us the recalled lot was made at a facility in Indiana, US adding that "After thorough investigation, no definitive root cause for the issue could be determined."
She also told us that "No shortages are likely" adding that "there is adequate product supply to meet patient demand."